CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
196-210 of 1225

Setting the Stage: Why Rethinking IBD Care Matters Now
MinuteCE®Setting the Stage: Why Rethinking IBD Care Matters Now

The Future of Biologic Treatment in IBD: What’s on the Horizon
MinuteCE®The Future of Biologic Treatment in IBD: What’s on the Horizon

Small Molecules in IBD: JAK Inhibitors and S1P Modulators
MinuteCE®Small Molecules in IBD: JAK Inhibitors and S1P Modulators

Translating Advances into Practice: Lessons from Today’s IBD Landscape
MinuteCE®Translating Advances into Practice: Lessons from Today’s IBD Landscape

Navigating IBD Guidelines: What Clinicians Need to Know Now
MinuteCE®Navigating IBD Guidelines: What Clinicians Need to Know Now

Gut-Selective Therapy: Understanding Anti-Integrins in IBD
MinuteCE®Gut-Selective Therapy: Understanding Anti-Integrins in IBD
- advertisement

Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
CME/CE Broadcast ReplaySeeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis

Putting It All Together: A Practical IBD Treatment Selection Primer
MinuteCE®Putting It All Together: A Practical IBD Treatment Selection Primer

Revisiting Anti-TNFs: Role, Risks, and Real-World Considerations
MinuteCE®Revisiting Anti-TNFs: Role, Risks, and Real-World Considerations

The Evolving Role of Small Molecules in IBD Care
MinuteCE®The Evolving Role of Small Molecules in IBD Care
- advertisement

Beyond One-Size-Fits-All: Individualizing First-Line IBD Treatment
MinuteCE®Beyond One-Size-Fits-All: Individualizing First-Line IBD Treatment

Targeting IL-23 Pathways: Evolving Biologic Strategies in IBD
MinuteCE®Targeting IL-23 Pathways: Evolving Biologic Strategies in IBD

Chairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
CME/CEChairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
































